When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are […] The post ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes appeared first on The Niche .